Welcome to our dedicated page for Atea Pharmaceuticals SEC filings (Ticker: AVIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Atea is a clinical-stage biopharmaceutical company focused on oral antiviral therapies for serious viral infections, and its filings help investors understand how it reports on clinical progress, financial condition and corporate governance.
Among the key documents are Form 8-K current reports, which Atea uses to announce material events such as quarterly financial results and related business updates. For example, 8-K filings dated August 7, 2025 and November 12, 2025 reference press releases detailing results of operations for the quarters ended June 30 and September 30, respectively, along with other matters described in those releases. These 8-Ks also confirm that Atea’s common stock is listed on The Nasdaq Global Select Market under the symbol AVIR.
Another important filing type is the proxy statement on Schedule 14A, summarized in a June 20, 2025 Form 8-K covering the company’s annual meeting of stockholders. That 8-K reports voting outcomes on the election of Class II directors, ratification of the independent registered public accounting firm and an advisory vote on executive compensation, providing insight into shareholder participation and governance decisions.
Through Stock Titan, users can track Atea’s ongoing Exchange Act reporting, including how it furnishes press releases as exhibits, discloses results of operations under Item 2.02 of Form 8-K, and reports shareholder meeting results under Item 5.07. Real-time updates from EDGAR are paired with AI-powered summaries that explain the structure and key points of filings, helping readers quickly identify items related to clinical-stage spending, cash balances, listing status on The Nasdaq Global Select Market and board or shareholder actions.
For those researching AVIR, this page offers a structured view of Atea’s regulatory history, from financial updates to governance matters, with tools to interpret the implications of each filing.
Form 4 highlights for Atea Pharmaceuticals, Inc. (AVIR)
- Reporting person: Bruce Polsky, Director.
- Transaction date: 20 Jun 2025; filing date 24 Jun 2025.
- Non-derivative shares: 29,600 common shares acquired at $0.00 upon RSU vesting; total direct ownership now 95,206 shares.
- New derivative grants:
- 29,600 Restricted Stock Units (RSUs) that vest on the earlier of the 2026 annual meeting or 1-year anniversary of grant.
- 41,200 stock options with a $3.25 exercise price, vesting monthly over 12 months and expiring 19 Jun 2035.
- Derivative disposition: 29,600 RSUs converted to common stock (code “M”), leaving zero balance for that award.
The filing reflects routine director equity compensation—no open-market buying or selling—and increases Mr. Polsky’s direct equity stake in AVIR. No cash outlay was required for the RSU conversion; the new option strike establishes the cost basis for potential future purchases.
Form 4 highlights for Atea Pharmaceuticals (AVIR): Director Jerome M. Adams reported several equity transactions on 20 June 2025.
- Common shares acquired: 29,600 shares were received upon conversion of previously vested restricted stock units (RSUs) at an effective price of $0.00 (code M). Adams now holds 62,750 AVIR shares directly.
- New equity awards granted:
- RSUs: 29,600 units granted (code A). They vest in a single installment on the earlier of the next annual meeting or the first anniversary of grant, subject to continued service.
- Stock options: 41,200 options granted with a $3.25 exercise price, expiring 19 June 2035. Vest monthly over 12 months, fully vested after one year.
- No derivative securities were sold; 29,600 RSUs were converted and the related derivative position is now zero.
Overall, the director increased his direct equity stake and received additional incentive-based awards, signaling continued alignment with shareholder interests.
Atea Pharmaceuticals (AVIR) filed a Form 4 on 24 Jun 2025 for director Bruno Lucidi covering transactions dated 20 Jun 2025.
- Common stock acquired: 29,600 shares were issued upon the full vesting and conversion of previously granted restricted stock units (RSUs) at a cost of $0, raising Lucidi’s direct holdings to 112,750 shares.
- New equity grants: (i) 29,600 RSUs that vest in a single tranche on the earlier of the next annual shareholder meeting or the first anniversary of grant; (ii) 41,200 stock options with a $3.25 exercise price, vesting in 12 equal monthly installments through 20 Jun 2026 and expiring on 19 Jun 2035.
- No open-market purchases or sales were reported; all activity reflects equity incentive awards and conversions.
The filing indicates continued insider equity ownership alignment, with a modest increase in direct share count and fresh long-term option incentives.
A Form 4 filed for Atea Pharmaceuticals, Inc. (AVIR) discloses that director Howard Berman received a new equity incentive award on 20 June 2025. The filing reports the grant of a stock option to purchase 164,800 shares of common stock at an exercise price of $3.25 per share. The option vests in 36 equal monthly installments beginning on the grant date and will be fully vested on 20 June 2028. It carries an expiration date of 19 June 2035. No acquisitions or dispositions of common shares were reported in Table I; the entire award is recorded in Table II as a derivative security held directly (Form D ownership). Following the grant, Berman’s reported beneficial ownership consists of 164,800 derivative securities tied to common stock. The transaction is coded “A,” indicating an award rather than a market purchase or sale.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) filed an 8-K summarising the results of its 20 June 2025 Annual Meeting of Stockholders.
- Quorum: 74,981,407 shares (≈87.6 % of outstanding) were represented in person or by proxy.
- Director elections (Class II, terms expiring 2028):
- Bruno Lucidi - 46,640,587 FOR / 12,559,084 WITHHOLD / 15,781,736 broker non-votes.
- Polly Murphy, DVM, PhD - 41,184,263 FOR / 18,015,408 WITHHOLD / 15,781,736 broker non-votes.
- Bruce Polsky, MD - 46,597,653 FOR / 12,602,018 WITHHOLD / 15,781,736 broker non-votes.
- Auditor ratification: KPMG LLP re-appointed for FY 2025 with 73,766,274 FOR, 1,192,659 AGAINST, 22,474 ABSTAIN; no broker non-votes.
- Say-on-pay (advisory): 46,450,302 FOR, 12,107,029 AGAINST, 642,340 ABSTAIN, 15,781,736 broker non-votes.
All three proposals passed. No other material business was disclosed in the filing.